Valeur202020212022202320242025Total du passif3.11 M785 K2.02 M9.15 M9.93 M15.56 MTotal des capitaux propres61.29 M56.88 M38.47 M10.23 M-1.32 M-9.78 MTotal du passif et des capitaux propres64.58 M57.7 M40.49 M19.38 M8.61 M5.78 MDette totale1.88 M0——2.31 M4.48 MDette nette1.88 M-48.27 M——-1.67 M-2.12 M
AIM ImmunoTech Inc. Common Stock
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees.
The company has created an immunomodulatory double stranded RNA drug called Ampligen.
It is also developing Ampligen to use as a treatment for multiple cancer tumor types, COVID-19 and chronic fatigue syndrome.